Maduck Sean's Form 4 filing
Corcept Therapeutics Inc (CORT) · filed Oct 12, 2023
- Accession no.
- 0000950170-23-053183
- Filed
- Oct 12, 2023
- Trade date
- Oct 10, 2023
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Checked
This filing lists 3 non-derivative transactions and 2 derivative transactions. Open-market sales total $504.1K. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Maduck SeanCIK 0001698310 | Officer (See Remarks) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Oct 10, 2023 | Common Stock | MOption exerciseAcquired | +8,471 | $3.02 | +$25,582.42 | 82,081 | Direct | |
| Oct 10, 2023 | Common Stock | MOption exerciseAcquired | +10,000 | $2.61 | +$26,100 | 92,081 | Direct | |
| Oct 10, 2023 | Common Stock | SSaleDisposed | −18,471 | $27.29F3 | −$504,073.59 | 73,291 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Oct 10, 2023 | Common Stock | MOption exerciseDisposed | −8,471 | $0.00 | $0 | 0 | Direct | |
| Oct 10, 2023 | Common Stock | MOption exerciseDisposed | −10,000 | $0.00 | $0 | 45,009 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F3
Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $27.24 to $27.435. Information on the exact number of shares sold at each sale price can be obtained from the issuer upon request.
Referenced by the price of 1 transaction in Table I.
Remarks
President, Corcept Endocrinology The power of attorney under which this form was signed is on file with the Commission.